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Copyright © 2007 AHC To determine the involvement of the non-receptor tyrosine kinase cSrc in plaque destabili-
zation in carotid atherosclerosis (CAS), which is responsible for cerebral infarction, we per-
formed quantitative and morphological detection of phosphorylated active cSrc (p-cSrc) and
histopathological examination in CAS lesions. We examined carotid endarterectomy speci-
mens obtained from 32 CAS patients. Each specimen was used for immunoblot and
immunohistochemical analyses of p-cSrc, histopathological analysis, and image analysis of
macrophage content. There was a strong positive correlation between cSrc activation on
blots and macrophage content on sections. When we defined the macrophage-rich plaque
(MRP) and the macrophage-poor plaque (MPP) as having macrophage content more and
less than 5%, respectively, the p-cSrc density and the occurrence of plaque hemorrhage and
thrombus formation were significantly increased in the MRP group (n=18) compared to the
MPP group (n=14). p-cSrc immunoreactivity was localized in lesional endothelial cells, macro-
phages, and smooth muscle cells, which contained proinflammatory substances: the upstream
oxidized low density lipoprotein, tissue factor and osteopontin, and the downstream active
forms of extracellular signal-activated kinase and p38 and nuclear factor-κB. Our results
suggest that cSrc activation in lesional cells contributes to plaque destabilization in CAS via
persistent inflammation.
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I. Introduction
Several investigations have indicated that carotid athero-
sclerosis (CAS) is a major cause of cerebral infarction [1].
Acute-onset ischemic brain attack occurring in CAS patients
results from acute occlusion of the lumen by atherothrom-
bosis or hemorrhage in the plaques or from thromboembo-
lism originating in atherothrombotic lesions [36, 37]. These
events associated with CAS appear to be based on plaque
instability, as described in studies on coronary atherosclero-
sis [11]. Emerging evidence suggests implications for
persistent inflammation in plaque destabilization of carotid
arteries [32]. Several studies on atherosclerosis of carotid
and coronary arteries have shown that plaques containing
a lot of macrophages are unstable, while those containing
only a few macrophages are stable [11, 24, 32, 36, 37].
It has been shown that vascular endothelial cells
(VECs), T-lymphocytes, and vascular smooth muscle cells
(VSMCs) as well as macrophages participate in atherogenic
inflammation [24, 32, 37]. VECs exposed to pathological
conditions including risk factors for atherosclerosis release
chemokines into blood and express cell adhesion molecules
(CAMs) on the apical cell surface. Chemokines stimulate
circulating monocytes to express integrin αMβ2 as the recep-
tor for CAMs, and the binding of CAMs to integrin αMβ2
induces monocyte transmigration into the subendothelial
vascular wall tissue. Migrating monocytes are transformed
to macrophages in the presence of monocyte colony-Toi et al. 154
stimulating factor released from T-lymphocytes. In athero-
sclerotic plaques, migrating VSMCs secrete collagen to
form neointima, while macrophages secrete matrix metallo-
proteinases to degrade the surrounding extracellular colla-
gen matrix. The latter leads to plaque destabilization, as evi-
denced by the vulnerability of the fibrous cap, followed by
ulceration, hemorrhage, rupture, and thrombus formation, or
both. Macrophages also secrete vascular endothelial growth
factor, resulting in neovascularization in the plaques. The
newly formed capillary vessels are mechanically vulnerable
and readily rupture to form hematoma in the plaques, so-
called plaque hemorrhage. All plaque-composing cells also
secrete several cytokines and growth factors. These obser-
vations would indicate the crosstalk between the lesional
cells in atherosclerotic plaques, and suggest that macrophage
content is a marker of inflammation and destabilization of
atherosclerotic plaques.
In atherogenesis, angiotensin II, oxidized low density
lipoprotein (OxLDL), activated factor VII (FVIIa), and
osteopontin have been shown to trigger inflammatory re-
sponse, by binding to their receptors: angiotensin II type 1
receptor (AT1R), scavenger receptor, tissue factor, and inte-
grin αVβ3, CD44 or fibronectin, respectively [3, 8, 21, 24,
26, 27, 35, 38]. Actually, recent in vivo studies have shown
increased levels of OxLDL, tissue factor, and osteopontin
in macrophage-rich or symptomatic plaques [10, 14, 23].
Moreover, atherothrombosis is enhanced in animals over-
expressing tissue factor [12] and osteopontin [6], while it is
attenuated in animals deficient in tissue factor [34] and
osteopontin [33]. These observations suggest critical roles
for tissue factor and osteopontin in atherogenesis. Several in
vitro studies have demonstrated that extracellular stimuli
induced by angiotensin II, OxLDL, tissue factor, and osteo-
pontin activate the non-receptor tyrosine kinase cSrc,
collectively. cSrc is a proto-oncogene product that was iden-
tified as an intracellular homologue of the Rous sarcoma
virus oncogene product vSrc [35]. cSrc is a 60 kDa protein,
expressed ubiquitously in several types of cells including
inflammatory cells, and localized in the cytosol under phys-
iological conditions. The binding of extracellular ligands,
such as growth factors, cytokines, factor VIIa, and osteopon-
tin, to their respective membrane-bound receptors results in
recruitment of the cytosolic cSrc to the intracellular domains
of the receptors followed by phosphorylation-mediated acti-
vation of cSrc. The activated cSrc starts inflammatory and
proliferative cell signaling via activation of mitogen-activat-
ed protein kinases (MAPKs) such as extracellular signal-
regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and
p38 as well as transcription factors including nuclear factor-
κB (NF-κB) [3–5, 7, 15, 21, 35]. However, it remains to be
determined whether cSrc activation may occur in association
with atherogenic inflammation and plaque destabilization in
vivo. To address this issue, we investigated morphological
and quantitative analyses of active form of cSrc phosphory-
lated at amino acid residue Y416 (p-cSrc) and verified the cor-
relation between macrophage content and cSrc activation in
CAS lesions. This is the first report concerning both immu-
nohistochemical detection and quantitative measurement of
p-cSrc in atherosclerotic plaques of human carotid arteries.
II. Materials and Methods
Subjects and tissue preparation
This study was approved by the Ethics Committee of
Tokyo Women’s Medical University and was carried out on
32 CAS patients [ages: 50–82 (69.7±8.2) y] who underwent
carotid endarterectomy (CEA). The clinical features of the
examined cases are summarized in Table 1. Each CEA spec-
imen was divided into equal two parts and processed for
making freshly frozen materials and 30% sucrose-immersed,
optical cutting temperature (OCT) compound-embedded
frozen materials. Both of them were stored at −80°C until
use.
Immunoblot analysis
The primary antibodies employed in immunoblotting
were mouse monoclonal IgG1 against p-cSrc (Clone 9A6,
Upstate, Lake Placid, NY, USA; 1:5,000) and mouse mono-
clonal IgG1 against β-actin (Clone AC-15, Sigma, St. Louis,
MO, USA; 1:10,000). Freshly frozen materials were homog-
enized with 10-fold volumes of radioimmunoprecipitation
assay (RIPA) buffer consisting of 50 mM Tris-buffered
saline, pH 7.5 (TBS), 1% sodium dodecyl sulfate (SDS),
1% glycerol, 1% deoxycholic acid, 0.1% Tween-20, and
0.3% 1,4-dithiothreitol (DTT) as well as the protease inhibi-
tor cocktail Complete Mini® (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s instructions. Ho-
Table 1. Clinical features of examined cases
ACEI, angiotensin II-converting enzyme inhibitor; ARB, angiotensin
II receptor blocker; TZD, thiazolidinedione.
Characteristics n %
Total number of subjects 32 100
Sex
Male 28 87.5
Female 4 12.5
Phenotype
Symptomatic case 12 37.5
Asymptomatic case 20 62.5
Risk factor
Hypertension 24 75
Hyperlipidemia 14 43.8
Diabetes mellitus 10 31.3
Smoking 10 31.3
Ischemic heart disease 13 40.6
Therapeutic drugs
Aspirin 28 87.5
Statin 9 28.1
Fibrate 0 0
TZD 0 0
ACEI 4 12.5
ARB 13 40.6cSrc Activation in Carotid Atherosclerosis 155
mogenates were centrifuged for 15 min at 4°C with 15,000 g
to obtain supernatant samples. Protein concentration of each
sample was measured by the Bradford method [29], and
samples were subsequently mixed with equal volume of
Laemmli’s buffer and boiled for 5 min. Aliquots of total
protein extracts (30 µg/lane) were loaded on a 10% SDS-
polyacrylamide gel, electrophoresed, and transferred onto a
polyvinylidene difluoride (PVDF) membrane (Millipore,
Tokyo, Japan). Blots were pretreated overnight at room tem-
perature with 5% bovine serum albumin (BSA) in TBS
containing 0.1% Tween-20 (TBS-T) solution, and then incu-
bated with the anti-p-cSrc antibody in Can Get Signal® solu-
tion (Toyobo, Tokyo, Japan) for 1 hr at room temperature
followed by horseradish peroxidase (HRP)-labeled anti-
mouse IgG antibody (DakoCytomation, Kyoto, Japan;
1:10,000) in Can Get Signal® solution for 1 hr at room tem-
perature. Immunoreaction for p-cSrc was visualized by
the chemiluminescence method using the ECL-plus kit (GE
Healthcare, Buckinghamshire, UK). Blots were then treated
for 30 min at 50°C with a stripping buffer composed of
50 mM TBS, 2% SDS, and 1% β-mercaptoethanol, rinsed
in TBS-T, treated overnight at room temperature with 5%
skim milk/TBS-T solution, and incubated with the anti-β-
actin antibody in 5% skim milk/TBS-T solution followed
by the HRP-labeled anti-mouse IgG antibody in 5% skim
milk/TBS-T solution. Immunoreaction for β-actin was de-
tected with the ECL kit (GE). Lanes processed with omis-
sion of the primary antibodies or by incubating with non-
immune mouse IgG served as negative reaction controls.
Immunoreactive signals for both p-cSrc and β-actin were
developed on an X-ray film, imported into a personal com-
puter using Photoshop image software, and quantitatively
measured using CS analyzer (ATTO, Tokyo, Japan). Optical
density of p-cSrc was normalized with that of β-actin in
each lane. The densitometric p-cSrc/β-actin data were used
for statistical analysis.
Histopathological analysis
Plaque morphology was histopathologically evaluated
on sections stained with hematoxylin-eosin (H&E), focusing
on the hallmarks of plaque instability such as ulceration,
hemorrhage, thrombus formation, and calcification. The
occurrence of these changes was statistically compared
between the examined plaques.
Immunohistochemical analysis
The primary antibodies employed in immunohisto-
chemistry were mouse monoclonal IgG1 against p-cSrc
(Clone 9A6; Upstate; 1:1,000), mouse monoclonal IgG1
against CD68 (Clone KP-1; DakoCytomation; 1:10,000),
mouse monoclonal IgG1 against α-smooth muscle actin
(SMA) (Clone 1A4; DakoCytomation; 1:1,000), mouse
monoclonal IgM against oxidized phosphatidylcholine
(OxPC) [13] (Clone DLH3; 1:3,000), mouse monoclonal
IgG1 against tissue factor (Clone 4509; American Diag-
nostica Inc., Stamford, CT, USA; 1:200), mouse monoclonal
IgG1 against osteopontin (Clone sc-21742; Santa Cruz Bio-
technology, Santa Cruz, CA, USA; 1:1,000), mouse mono-
clonal IgG2a against active form of ERK phosphorylated at
Y204 (p-ERK) (Clone sc-7383; Santa Cruz; 1:200), rabbit
polyclonal IgG against active form of p38 phosphorylated
at Y182 (p-p38) (Cat. No. sc-7975-R; Santa Cruz; 1:200),
and goat polyclonal IgG against NF-κB (Cat. No. sc-109-G;
Santa Cruz; 1:200). CD68, SMA, and OxPC were used as
markers of macrophage, VSMC, and OxLDL, respectively.
Tissue factor and osteopontin were markers of proinflam-
matory gene products. p-ERK, p-p38, and NF-κB served as
markers of proinflammatory cell signaling.
Multiple 6-µm-thick frozen sections cut from OCT
compound-embedded frozen materials were postfixed for 10
min at 4°C in 100% acetone, rinsed in 150 mM phosphate-
buffered saline, pH 7.6 (PBS), quenched for 10 min with 3%
H2O2, rinsed in PBS, treated for 20 min at room temperature
with 3% BSA or 3% skim milk in PBS, processed with the
Avidin/Biotin blocking kit (Vector Laboratories, Burlin-
game, CA, USA) according to the manufacturer’s instruc-
tions, and then incubated overnight at 4°C with the primary
antibodies. Immunoreaction was visualized by the avidin-
biotin-immunoperoxidase complex (ABC) method using
the appropriate Vectastain ABC kits (Vector) according to
the manufacturer’s instructions. The chromogen was 3,3'-
diaminobenzidine hydrochloride (DAB), and the counter-
stain was hematoxylin. Negative reaction control sections
were obtained by omission of the primary antibodies or by
incubating with nonimmune IgG derived from the same
animal species as those producing the antibodies. Immuno-
stained sections were observed with a light microscope
(Olympus, Tokyo, Japan), and immunohistochemical local-
ization of p-cSrc was identified by comparison with con-
secutive sections stained with H&E and immunostained for
CD68, SMA, OxPC, tissue factor, osteopontin, p-ERK, p-
p38, and NF-κB. In addition, immunohistochemical local-
ization of p-cSrc was strictly verified by comparison with
that of p-p38 and NF-κB using the double immunostaining
method. Briefly, sections were incubated with the rabbit
anti-p-p38 antibody or the goat anti-NF-κB antibody, and
immunoreaction was detected by the ABC method with
DAB as the chromogen. After photomicrographing immuno-
reactive structures, the immunostained sections were then
incubated with the mouse anti-p-cSrc antibody, and immuno-
reaction was detected by the polymer-immunocomplex
method using the Envision system kit (DakoCytomation)
with NiCl2/DAB as the chromogen. The location of the
p-cSrc determinants (blue) was compared with the initially
taken photographs of the p-p38 and NF-κB determinants
(brown). Thus, appearance of ‘dark blue stain’ was con-
sidered as the colocalization of the blue pigments with the
brown pigments.
Image analysis
To quantify macrophage content in CAS lesions, the
proportion of CD68-immunoreactive area in each plaque
was measured by image analysis. In brief, sections immu-
nostained for CD68 were observed by light microscopy, andToi et al. 156
the photogenic data were digitally imported into a personal
computer using Photoshop image software. Both the CD68-
immunoreactive area (mm2) and the total area (mm2) in a
plaque were measured using NIH image software.
Statistics
The relationship between macrophage content and cSrc
activation in the examined cases was statistically verified by
nonparametric correlation analysis. Macrophage content in
each plaque was expressed as a percentage of the CD68-im-
munoreactive area in the total area on a section. cSrc activa-
tion in each plaque was expressed as a relative value of the
densitometric p-cSrc/β-actin ratio on a lane. Linear equation
(y=ax+b) and correlation coefficient (r) were obtained, and
r value more than 0.6 was considered to be strongly cor-
related. The examined lesions were then divided into
macrophage-rich plaques (MRPs) and macrophage-poor
plaques (MPPs), as described previously [23]; MRPs and
MPPs were defined as having macrophage content more
than 5% and less than 5%, respectively. The densitometric
p-cSrc/β-actin data in the MRP and MPP groups were
expressed as mean±standard deviation, and compared by
unpaired Student’s t-test between the two groups. The histo-
pathological findings were compared by using chi square
test between the two groups. P value less than 0.05 was
considered statistically significant.
III. Results
Relationship between macrophage content and cSrc 
activation
Immunoreactive signals for p-cSrc and β-actin ap-
peared on immunoblots at 66 kDa and 42 kDa, respectively
(Fig. 1A). No immunoreaction product was detectable on
negative reaction control lanes. There was a strong positive
correlation between the CD68-immunoreactive areas on sec-
tions and the optical p-cSrc densities on blots (Fig. 1B). The
32 examined cases were divided into 14 MPP cases and 18
MRP cases. Unpaired Student’s t-test revealed that the opti-
cal p-cSrc densities on blots were significantly increased in
the MRP group compared to the MPP group (Fig. 1C).
Comparison of histopathological findings between the MPP 
and MRP groups
The histopathological findings were compared by chi
square test between the MRP and MPP groups (Table 2).
Based on the hallmarks of plaque instability, the occurrence
of plaque hemorrhage and thrombus formation significantly
increased in the MRP group than in the MPP group. By con-
trast, there was no significant difference in the occurrence of
ulceration and calcification of the CAS plaques between the
two groups.
Immunohistochemical observations of p-cSrc and related 
substances
No immunoreaction product deposit was visible on
negative reaction control sections (data not shown). At a low
Fig. 1. Quantitative measurements of p-cSrc in CEA specimens. (A)
Representative results of immunoblotting of p-cSrc and β-actin
detected by the chemiluminescence method. (B) Correlation
between macrophage content and cSrc activation. (C) Comparison
of cSrc activation levels between the MPP and MRP groups. CEA,
carotid endarterectomy; MPP, macrophage-poor plaque; MRP,
macrophage-rich plaque; NRC, negative reaction control; p-cSrc,
active form of cSrc phosphorylated at Y416.
Table 2. Comparison of histopathological features between the two
groups
MPP, macrophage-poor plaque; MRP, macrophage-rich plaque; NS,
not significant.
Characteristics MPP group 
(cases)
MRP group 
(cases) P value
Number of subjects 14 18
Plaque morphology
Ulceration 2 3 NS
Hemorrhage 3 13 0.011
Thrombus formation 0 9 0.0018
Calcification 12 16 NScSrc Activation in Carotid Atherosclerosis 157
magnification, p-cSrc immunoreactivity was distributed in
the CAS plaques (Fig. 2), and seemed to increase in the
MRP group compared with the MPP group. The distribution
of p-cSrc appeared to overlap with that of CD68 and SMA to
some extent; however, the cSrc immunoreactivity was less
intense in large foamy macrophages neighboring the lipid
core. At a higher magnification, p-cSrc immunoreactivity
was localized in the cytoplasm of VECs lining the inner
surface of carotid arteries and newly formed capillary ves-
sels in atherosclerotic lesions as well as macrophages and
migrating VSMCs (Fig. 3). p-cSrc immunoreactivity in
the cytoplasm of these lesional cells was colocalized with
OxPC, tissue factor, osteopontin, p-ERK, p-p38, and NF-κB
(Fig. 4). NF-κB immunoreactivity was also localized in the
nucleus of the lesional cells.
IV. Discussion
In the present study, it is noteworthy that p-cSrc was
detected in human CAS lesions. There was a strong positive
correlation between the CD68-immunoreactive areas on sec-
tions and the p-cSrc-immunoreactive densities on blots. This
suggests that cSrc activation is enhanced in parallel with an
increase in macrophage content in atherosclerotic lesions.
The fact that both plaque hemorrhage and thrombus forma-
tion as the histopathological hallmarks of plaque instability
were more common in the MRP group than in the MPP
group shows the close relevance between macrophage con-
tent and plaque destabilization, as previously discussed [16].
The lack of difference in the occurrence of calcification
between the two groups suggests dual roles for osteopontin
in atherogenesis, including plaque inflammation and extra-
cellular calcification. Furthermore, p-cSrc immunoreactivity
was localized in VECs, macrophages, and VSMCs in CAS
plaques. Several experimental studies have indicated that
macrophage content in atherosclerotic lesions reflects in-
flammatory activity and plaque instability [11, 24, 32, 36,
37]. Given these observations, cSrc activation in lesional
cells may be involved in inflammation and instability of
atherosclerotic lesions.
Some in vitro studies have demonstrated that the bind-
ing of OxLDL, FVIIa, and osteopontin to their specific re-
ceptors gives rise to cSrc activation, resulting in the activa-
tion of inflammatory cell signaling [17, 24, 35]. In relation
to this, we demonstrated the colocalization of p-cSrc with
OxLDL, tissue factor, and osteopontin in lesional cells such
as VECs, macrophages, and VSMCs. After uptake into the
lesional cells via scavenger receptors, OxLDL in the cyto-
plasm activates cSrc [9, 17, 20]. It is known that inflamed
plaques have greater levels of the hepatocyte-produced,
plasma-mediated FVIIa, as a result of increased endothelial
permeability in the lesions. This leads to increased chances
of FVIIa binding to the receptor tissue factor, resulting in
cSrc activation [8, 26–28, 35]. Similarly, osteopontin bind-
ing to the receptor integrin αVβ3, CD44 or fibronectin
induces cSrc activation [24]. In addition, the binding of
angiotensin II, one of the most important factors involved
in atherogenesis, to AT1R also brings about cSrc activation
[3, 21, 30]. These studies attributed cSrc activation to in-
creased oxidative stress and cytosolic calcium levels.
It has been shown that cSrc activation exerts critical
effects on the induction of proinflammatory gene products
via activation of the MAPK pathway and the NF-κB path-
way [3–5, 7, 8, 15, 21, 26, 27, 35, 38]. In relation to this, we
demonstrated the colocalization of p-cSrc with p-ERK, p-
p38, and NF-κB in CAS lesions, as previously described [19,
21, 22, 25, 31]. Several experimental studies have shown
that activated cSrc catalyzes the phosphorylation of phospha-
tidyl inositol 3-kinase (PI3K) and protein kinase C (PKC) [4,
5, 7, 8, 15, 26, 27, 35] to activate them. PI3K activates ERK
and p38 via activation of Ras and Rac1, respectively, while
PKC activates ERK and NF-κB via activation of Raf-1 and
inhibitor of κB kinase, respectively. Alternatively, both the
Fig. 2. Loupe findings of consecutive MPP and MRP sections
immunostained for p-cSrc, CD68, and SMA. Immunoreaction on
all sections is visualized by the ABC method with DAB as the chro-
mogen (brown). Bar=1 mm. ABC, avidin-biotin-immunoperoxi-
dase complex; DAB, 3,3'-diaminobenzidine tetrahydrochloride;
MPP, macrophage-poor plaque; MRP, macrophage-rich plaque; p-
cSrc, active form of cSrc phosphorylated at Y416; SMA, α-smooth
muscle actin.Toi et al. 158
MAPK and NF-κB pathways induce tissue factor [2, 18, 22]
and osteopontin [38], which have been shown to be over-
expressed in symptomatic CAS plaques [10, 14]. Moreover,
both the binding of FVIIa and osteopontin to their specific
receptors, as mentioned above, consequently induce cSrc
activation again. Thus, it is likely that cSrc activation may
contribute to persistent inflammation in CAS lesions.
Collectively, we demonstrated the following four find-
ings using CEA specimens: (1) the strong positive correla-
tion between macrophage content and cSrc activation, (2)
the increased vulnerability of MRPs compared to MPPs,
(3) the localization of p-cSrc in VECs, macrophages, and
VSMCs, and (4) the colocalization of p-cSrc with the up-
stream OxLDL, tissue factor, and osteopontin and the down-
stream activated ERK, p38, and NF-κB. Our results suggest
that cSrc activation in lesional cells mediates persistent in-
flammation in CAS plaques and contributes to plaque desta-
bilization, and point to the possibility that the inhibition of
cSrc may ameliorate these pathological conditions. Recent
investigations have documented implications for cSrc acti-
vation in transactivation and nuclear translocation of the
transcription factor signal transducer and activator of tran-
scription (STAT) in atherosclerosis models [21, 39]. Little is
known, however, about the relationship between cSrc and
STAT in atherogenesis. Answers to this and other questions
concerning the modulation of cSrc activity need to be ad-
dressed to further the understanding of the pathomechanism
of plaque destabilization and the prevention of ischemic
events in the brain.
Fig. 3. Photomicrographs of MRP sections immunostained for p-cSrc (A–C, E), CD68 (D) and SMA (F). Sections (C, E) are consecutive to sec-
tions (D, F), respectively. Immunoreaction on all sections is visualized by the ABC method with DAB as the chromogen (brown). Arrowheads,
blank arrows, and solid arrows indicate VECs, macrophages, and VSMCs, respectively. Bar=50 µm (A–F). ABC, avidin-biotin-immunoperox-
idase complex; DAB, 3,3'-diaminobenzidine tetrahydrochloride; MRP, macrophage-rich plaque; p-cSrc, active form of cSrc phosphorylated at
Y416; SMA, α-smooth muscle actin; VECs, vascular endothelial cells; VSMCs, vascular smooth muscle cells.cSrc Activation in Carotid Atherosclerosis 159
Fig. 4. Photomicrographs of MRP sections immunostained for p-cSrc (D–F, J–L), OxPC (A), tissue factor (B), osteopontin (C), p-ERK (G), p-
p38 (H), and NF-κB (I). Panels (A–C, G) indicate identical regions to panels (D–F, H), respectively, on consecutive sections. Panels (H, I)
indicate identical regions to panels (K, L), respectively, on the same sections. Immunoreaction on all sections is visualized by the ABC method
with DAB as the chromogen (brown) (A–L), and in addition, panels (K, L) show double immunostaining for p-cSrc on panels (H, I), respec-
tively, by the PIC method with DAB/NiCl2 as the chromogen (blue & brown). Arrowheads, blank arrows, and solid arrows indicate VECs,
macrophages, and VSMCs, respectively. Bar=50 µm (A–L). ABC, avidin-biotin-immunoperoxidase complex; DAB, 3,3'-diaminobenzidine
tetrahydrochloride; MRP, macrophage-rich plaque; NF-κB, nuclear factor-κB; OxPC, oxidized phosphatidylcholine; p-cSrc, active form of
cSrc phosphorylated at Y416; p-ERK, active form of extracellular signal-regulated kinase phosphorylated at Y204; PIC, polymer-immunocom-
plex; p-p38, active form of p38 mitogen-activated protein kinase phosphorylated at Y182.Toi et al. 160
V. Acknowledgments
We wish to thank Drs. Makoto Iwata, Yoshikazu
Okada, Takakazu Kawamata, Akitsugu Kawashima, and
Yoichiro Kato for their valuable suggestions. We also wish
to express our special thanks to Dr. Hiroyuki Itabe for
generously donating the anti-OxPC antibody (DLH3).
VI. References
1. Adams, H. P., Del Zoppo, G., Alberts, M. J., Bhatt, D. L., Brass,
L., Furlan, A., Grubb, R. L., Higashida, R. T., Jauch, E. C.,
Kidwell, C., Lyden, P. D., Morgenstern, L. B., Qureshi, A. I.,
Rosenwasser, R. H., Scott, P. A. and Wijdicks, E. F. M. (2007)
Guidelines for early management of adults with ischemic stroke:
a guideline from the American Heart Association/American
Stroke Association Stroke Council, Clinical Cardiology Council,
Cardiovascular Radiology and Intervention Council, and the
Atherosclerotic Peripheral Vascular Disease and Quality of Care
Outcomes in Research Interdisciplinary Working Groups: the
American Academy of Neurology affirms the value of this guide-
line as an educational tool for neurologists. Stroke  38; 1655–
1711.
2. Bohgaki, N., Atsumi, T., Yamashita, Y., Yasuda, S., Sakai, Y.,
Furusaki, A., Bohgaki, T., Amengual, O., Amasaki, Y. and Koike,
T. (2004) The p38 mitogen-activated protein kinase (MAPK)
pathway mediates induction of the tissue factor gene in mono-
cytes stimulated with human monoclonal anti-β2 glycoprotein I
antibodies. Int. Immunol. 16; 1633–1641.
3. Bokemeyer, D., Schmitz, U. and Kramer, H. J. (2000) Angio-
tensin II-induced growth of vascular smooth muscle cells requires
an Src-dependent activation of the epidermal growth factor recep-
tor. Kid. Int. 58; 549–558.
4. Bouchard, V., Demers, M. J., Thibodeau, S., Laquerre, V., Fujita,
N., Tsuruo, T., Beaulieu, J. F., Gauthier, R., Vézina, A.,
Villeneuve, L. and Vachon, P. H. (2007) Fak/Src signaling in
human intestinal epithelial cell survival and anoikis: differentia-
tion state-specific uncoupling with the PI3-K/Akt-1 and MEK/
Erk pathways. J. Cell. Physiol. 212; 717–728.
5. Chang, Y. J., Wu, M. S., Lin, J. T., Sheu, B. S., Muta, T., Inoue,
H. and Chen, C.-C. (2004) Induction of cyclooxygenase-2 over-
expression in human gastric epithelial cells by Helicobacter
pylori involves TLR2/TLR9 and c-Src dependent nuclear factor-
κB activation. Mol. Pharmacol. 66; 1465–1477.
6. Chiba, S., Okamoto, H., Kon, S., Kimura, C., Murakami, M.,
Inobe, M., Matsui, Y., Sugawara, T., Shimizu, T., Ueda, T. and
Kitabatake, A. (2002) Development of atherosclerosis in osteo-
pontin transgenic mice. Heart Vessels 16; 111–117.
7. Cho, H.-M., Choi, S. H., Hwang, K.-C., Oh, S.-Y., Kim, H.-G.,
Yoon, D.-H., Choi, M.-A., Lim, S., Song, Y., Jang, Y. and Kim, T.
W. (2005) The Src/PLC/PKC/MEK/ERK signaling pathway is
involved in aortic smooth muscle cell proliferation induced by
glycated LDL. Mol. Cells 19; 60–66.
8. Cirillo, P., Calì, G., Golino, P., Calabrò, P., Forte, L., De Rosa, S.,
Pacileo, M., Ragni, M., Scopacasa, F., Nitsch, L. and Chiariello,
M. (2004) Tissue factor binding of activated factor VII triggers
smooth muscle cell proliferation via extracellular signal-regulated
kinase activation. Circulation 109; 2911–2916.
9. Foncea, R., Carvajal, C., Almarza, C. and Leighton, F. (2000)
Endothelial cell oxidative stress and signal transduction. Biol.
Res. 33; 89–96.
10. Golledge, J., McCann, M., Mangan, S., Lam, A. and Karan, M.
(2004) Osteoprotegerin and osteopontin are expressed at high
concentrations within symptomatic carotid atherosclerosis. Stroke
35; 1636–1641.
11. Hansson, G. K. (2005) Inflammation, atheroslecrosis, and coro-
nary artery disease. N. Engl. J. Med. 352; 1685–1695.
12. Hasenstab, D., Lea, H., Hart, C. E., Lok, S. and Clowes, A. W.
(2000) Tissue factor overexpression in rat arterial neointima
models thrombosis and progression of advanced atherosclerosis.
Circulation 101; 2651–2657.
13. Itabe, H., Takeshima, E., Iwasaki, H., Kimura, J., Yoshida, Y.,
Imanaka, T. and Takano, T. (1994) A monoclonal antibody
against oxidized lipoprotein recognizes foam cells in atheroscle-
rotic lesions. J. Biol. Chem. 269; 15274–15279.
14. Jander, S., Sitzer, M., Wendt, A., Schroeter, M., Buchkremer, M.,
Siebler, M., Müller, W., Sandmann, W. and Stoll, G. (2001) Ex-
pression of tissue factor in high-grade carotid artery stenosis.
Association with plaque destabilization. Stroke 32; 850–854.
15. Kanda, Y. and Watanabe, Y. (2005) Thrombin-induced glucose
transport via Src-p38 MAPK pathway in vascular smooth muscle
cells. Br. J. Pharmacol. 146; 60–67.
16. Lee, R. T. and Libby, P. (1997) The unstable atheroma. Arterio-
scler. Thromb. Vasc. Biol. 17; 1859–1867.
17. Leonarduzzi, G., Arkan, M. C., Basaga, H., Chiarpotto, E.,
Sevenian, A. and Poli, G. (2000) Lipid oxidation products in
cell signaling. Free Radic. Biol. Med. 28; 1370–1378.
18. López-Pedrera, C., Buendía, P., Cuadrado, M. J., Siendones, E.,
Aguirre, M. A., Barbarroja, N., Montiel-Duarte, C., Torres, A.,
Khamashta, M. and Velasco, F. (2006) Antiphospholipid anti-
bodies from patients with the antiphospholipid syndrome induce
monocyte tissue factor expression through the simultaneous acti-
vation of NF-κB/Rel proteins via the p38 mitogen-activated pro-
tein kinase pathway, and of the MEK-1/ERK pathway. Arthritis
Rheum. 54; 301–311.
19. Martin-Ventura, J. L., Blanco-Colio, L. M., Muñoz-Garcia, B.,
Gómez-Hernández, A., Arribas, A., Ortega, L., Tuñon, J. and
Egido, J. (2004) NF-κB activation and Fas ligand overexpression
in blood and plaques of patients with carotid atherosclerosis.
Potential implication in plaque instability. Stroke 35; 458–463.
20. Maschberger, P., Bauer, M., Baumann-Siemons, J., Zangl, K. J.,
Negrescu, E. V., Reininger, A. J. and Siess, W. (2000) Mildly ox-
idized low density lipoprotein rapidly stimulates via activation of
the lysophosphatidic acid receptor Src family and Syk tyrosine
kinases and Ca2+ influx in human platelets. J. Biol. Chem. 275;
19159–19166.
21. Mheta, P. K. and Griendling, K. K. (2007) Angiotensin II cell sig-
naling: physiological and pathological effects in the cardiovascu-
lar system. Am. J. Physiol. Cell Physiol. 292; C82–C97.
22. Monaco, C., Andreakos, E., Kiriakidis, S., Mauri, C., Bicknell,
C., Foxwell, B., Cheshire, N., Paleolog, E. and Feldmann, M.
(2004) Canonical pathway of nuclear factor κB activation selec-
tively regulates proinflammatory and prothrombotic responses in
human atherosclerosis. Proc. Natl. Acad. Sci. U S A 101; 5634–
5639.
23. Nishi, K., Itabe, H., Uno, M., Kitazato, K. T., Horiguchi, H.,
Shinno, K. and Nagahiro, S. (2002) Oxidized LDL in carotid
plaques and plasma associates with plaque instability. Arterio-
scler. Thromb. Vasc. Biol. 22; 1649–1654.
24. Ohsuzu, F. (2004) The roles of cytokines, inflammation and im-
munity in vascular diseases. J. Atheroscler. Thromb. 11; 313–321.
25. Omura, T., Yoshiyama, M., Izumi, Y., Kim, S., Matsumoto, R.,
Enomoto, S., Kusuyama, T., Nishuya, D., Nakamura, Y., Akioka,
K., Iwao, H., Takeuchi, K. and Yoshikawa, J. (2005) Involvement
of c-Jun NH2 terminal kinase and p38MAPK in rapamycin-medi-
ated inhibition of neointimal formation in rat carotid arteries. J.
Cardiovasc. Pharmacol. 46; 519–525.
26. Ott, I., Weigand, B., Michl, R., Seitz, I., Sabbari-Erfani, N.,
Neumann, F. J. and Schömig, A. (2005) Tissue factor cytoplasmic
domain stimulates migration by activation of the GTPase Rac1
and the mitogen-activated protein kinase p38. Circulation 111;
349–355.cSrc Activation in Carotid Atherosclerosis 161
27. Poulsen, L. K., Jacobsen, N., Sørensen, B. B., Bergenhem, N. C.
H., Kelly, J. D., Foster, D. C., Thastrup, O., Ezban, M. and
Petersen, L. C. (1998) Signal transduction via the mitogen-
activated protein kinase pathway induced by binding of coagula-
tion factor VIIa to tissue factor. J. Biol. Chem. 273; 6228–6232.
28. Price, G. C., Thompson, S. A. and Kam, P. C. A. (2004) Tissue
factor and tissue factor pathway inhibitor. Anaesthesia 59; 483–
492.
29. Sapan, C. V., Lundblad, R. L. and Price, N. C. (1999) Colorimet-
ric protein assay techniques. Biotechnol. Appl. Biochem. 29; 99–
108.
30. Seshiah, P. N., Weber, D. S., Rocic, P., Valppu, L., Taniyama, Y.
and Griendling, K. K. (2002) Angiotensin II stimulation of
NAD(P)H oxidase activity. Upstream mediators. Circ. Res. 91;
406–413.
31. Squadrito, F., Minutoli, L., Esposito, M., Bitto, A., Marini, H.,
Seminara, P., Crisafuli, A., Passaniti, M., Adamo, E. B., Marini,
R., Guarini, S. and Altavilla, D. (2005) Lipid peroxidation
triggers both c-Jun N-terminal kinase (JNK) and extracellular-
regulated kinase (ERK) activation and neointimal hyperplasia
induced by cessation of blood flow in the mouse carotid artery.
Atherosclerosis 178; 295–302.
32. Stoll, G. and Bendszus, M. (2006) Inflammation and atherosclero-
sis. Novel insights into plaque formation and destabilization.
Stroke 37; 1923–1932.
33. Ström, Å., Franzén, A., Wännerud, C., Knutsson, A.-K.,
Heinegård, D. and Hultgårdh-Nilsson, A. (2004) Altered vascular
remodeling in osteopontin-deficient atherosclerotic mice. J.
Vasc. Res. 41; 314–322.
34. Tilley, R. E., Pedersen, B., Pawlinski, R., Sato, Y., Erlich, J. H.,
Shen, Y., Day, S., Huang, Y., Eitzman, D. T., Boisvert, W. A.,
Curtiss, L. K., Fay, W. P. and Mackman, N. (2006) Atherosclero-
sis in mice is not affected by a reduction in tissue factor expres-
sion. Arterioscler. Thromb. Vasc. Biol. 26; 555–562.
35. Versteeg, H. H., Hoedemaeker, I., Diks, S. H., Stam, J. C.,
Spaargaren, M., Van Bergen En Henegouen, P. M. P., Van
Deventer, S. J. H. and Peppelenbosch, M. P. (2000) Factor
VIIa/tissue factor-induced signaling via activation of Src-like
kinases, phosphatidylinositol 3-kinase, and Rac. J. Biol. Chem.
275; 28750–28756.
36. Viles-Gonzalez, J. F., Anand, S. X., Valdiviezo, C., Zafar, M. U.,
Hutter, R., Sanz, J., Rius, T., Poon, M., Fuster, V. and Badimon, J.
J. (2004) Update in atherothrombotic disease. Mount Sainai J.
Med. 71; 197–208.
37. Virmani, R., Ladich, E. R., Burke, A. P. and Kolodgie, F. D.
(2006) Histopathology of carotid atherosclerotic disease. Neuro-
surgery 59 (Suppl); S3-219–S3-229.
38. Xie, Z., Pimental, D. R., Lohan, S., Vasertriger, A., Pligavko, C.,
Colucci, W. S. and Singh, K. (2001) Regulation of angiotensin II-
stimulated osteopontin expression in cardiac microvascular endo-
thelial cells: role of p42/44 mitogen-activated protein kinase and
reactive oxygen species. J. Cell Physiol. 188; 132–138.
39. Yeh, M., Gharavi, N. M., Choi, J., Hsieh, X., Reed, E.,
Mouillesseaux, K. P., Cole, A. L., Reddy, S. T. and Berliner, J. A.
(2004) Oxidized phospholipids increase interleukin 8 (IL-8)
synthesis by activation of the c-src/signal transducers and acti-
vators of transcription (STAT) 3 pathway. J. Biol. Chem. 279;
This is an open access article distributed under the Creative Commons Attribu-
tion License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
30175–30181.